RxDoctor Payments Data

Carl Huntoon

Psychiatric/Mental Health · Alma, MINPI 1649883653

Payments from drug & device makers

$1,580in general payments, 2019–2025

Across 94 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$377
  • Johnson & Johnson$303
  • Alkermes, Inc.$226
  • AbbVie$140
  • Otsuka America Pharmaceutical, Inc.$124
  • Teva Pharmaceuticals USA, Inc.$114
  • plus $295 from 6 others

What the payments were for

  • Food & beverage$1,56699%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,580 in reported general payments places this provider in the 70th percentile of 638 psychiatric/mental health providers in Michigan.

See all psychiatric/mental health providers in Michigan

Medicare billing

Part B allowed, 2024
$8,728
Medicare patients
31
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide19$9,631
Lurasidone Hcl19$6,587
Mirtazapine102$851
Aripiprazole22$681
Vilazodone Hcl11$646
Duloxetine Hcl47$563
Venlafaxine Hcl ErVenlafaxine Hcl56$553
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$376
Trazodone Hcl56$300
Lamotrigine27$299
Buspirone Hcl30$274
Escitalopram Oxalate27$258
Sertraline Hcl38$256
Olanzapine14$206
Donepezil Hcl15$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$88$9,63119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 638 psychiatric/mental health providers in Michigan.

Other psychiatric/mental health in Alma

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →